Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors

Journal of Clinical Oncology

Volumn 23, Issue 9, 2005, Pages 1885-1893

  Grem, Jean L ^a   Morrison, Geraldine ^a   Guo, Xiao Du ^a   Agnew, Elizabeth ^a   Takimoto, Chris H ^a   Thomas, Rebecca ^a   Szabo, Eva ^a   Grochow, Louise ^a   Grollman, Frank ^a   Hamilton, J Michael ^a   Neckers, Len ^a   Wilson, Richard H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; HEAT SHOCK PROTEIN 70; PROTEIN KINASE LCK; RAF PROTEIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; MACROCYCLIC LACTAM; RIFABUTIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL LYSATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MONITORING; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRANULOCYTE TOXICITY; HEPATIC TRANSAMINITIS; HEPATITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOBLOTTING; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PLATELET TOXICITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; URINARY EXCRETION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AREA UNDER CURVE; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS, MACROCYCLIC; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS; RIFABUTIN;

EID: 20144375312     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.085     Document Type: Article

References (39)

1. DeBoer C, Meulman PA, Wnuk RJ, et al: Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442-447, 1970
2. Schulte TW, Neckers LM: The benzoquinone ansamycin 17-allylamino-17- demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273-279, 1998
3. Ochel HJ, Eichhorn K, Gademann G: Geldanamycin: The prototype of a class of anti-tumor drugs targeting the heat shock protein 90 family of molecular chaperones. Cell Stress Chaperones 6:105-112, 2001
4. Neckers L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:355-61, 2002 (suppl)
5. Blagosklonny MV: Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia 16:455-462, 2002
6. Fliss AE, Benzeno S, Rao J, et al: Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 72:223-230, 2000
7. Smith DF, Whitesell L, Nair SC, et al: Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 15:6804-6812, 1995
8. Vanaja DK, Mitchell SH, Toft DO, et al: Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7:55-64, 2002
9. Supino-Rosin L, Yoshimura A, Yarden Y, et al: Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins. J Biol Chem 275:21850-21855, 2000
10. Munster PN, Marchion DC, Basso AD, et al: Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 62:3132-3137, 2002
11. Bucci M, Roviezzo F, Cicala C, et al: Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br J Pharmacol 131:13-16, 2000
12. Whitesell L, Mimnaugh EG, De Costa B, et al: Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324-8328, 1994
13. An WG, Schulte TW, Neckers LM: The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355-360, 2000
14. Bijlmakers MJ, Marsh M: Hsp90 is essential for the synthesis and subsequent membrane association, but not the maintenance, of the Src-kinase p56(lck). Mol Biol Cell 11:1585-1595, 2000
15. Nimmanapalli R, O'Bryan E, Bhalla K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61:1799-1804, 2001
16. Schulte TW, Blagosklonny MV, Ingui C, et al: Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270:24585-24588, 1995
17. Whitesell L, Sutphin P, An WG, et al: Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogens 14:2809-2816, 1997
18. Whitesell L, Sutphin PD, Pulcini EJ, et al: The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 18:1517-1524, 1998
19. Mabjeesh NJ, Post DE, Willard MT, et al: Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478-2482, 2002
20. Prodromou C, Roe SM, O'Brien R, et al: Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65-75, 1997
21. Grenert JP, Sullivan WP, Fadden P, et al: The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850, 1997
22. Stebbins CE, Russo AA, Schneider C, et al: Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 89:239-250, 1997
23. Supko JG, Hickman RL, Grever MR, et al: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315, 1995
24. Page J, Heath J, Fulton R, et al: Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc Am Assoc Cancer Res 38:308, 1997 (abstr 2067)
25. Egorin MJ, Rosen DM, Wolff JH, et al: Metabolism of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58: 2385-2396, 1998
26. Egorin MJ, Zuhowski EG, Rosen DM, et al: Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291-302, 2001
27. Wilson RH, Takimoto CH, Agnew EB, et al: Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:82a, 2001 (abstr 325)
28. Agnew EB, Wilson RH, Morrison G, et al: Clinical pharmacokinetics of 17-(allylamino)-17-demethoxygeldanaymcin and the active metabolite 17-(amino)-demethoxygeldanamycin given as a one-hour infusion daily for 5 days. Proc Am Assoc Cancer Res 43:272, 2002 (abstr 1349)
29. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
30. Agnew EB, Wilson RH, Grem JL, et al: Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237-243, 2001
31. Marcu MG, Doyle M, Bertolotti A, et al: Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 22:8506-8513, 2002
32. Marcu M, Schulte TW, Neckers LM: Novobiocin and other coumarin antibiotics bind to heat shock protein 90 and result in the degradation of hsp90-dependent signaling proteins p185erbB2, p60v-src, raf-1 and mutated p53. J Natl Cancer Inst 92:242-248, 2000
33. Munster PN, Tong W, Schwartz L, et al: Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 20:82a, 2001 (abstr 327)
34. Goetz M, Toft D, Reid J, et al: A phase I trial of 17-allyl-amino- geldanamycin in patients with advanced cancer. Eur J Cancer 38:54, 2002 (suppl 7, abstr 170)
35. Banerji U, O'Donnell A, Scurr M, et al: Phase I trial of the heat shock protein 90 (hsp90) inhibitor 17-allylamino 17-demethoxygeldanamycin: Pharmacokinetic profile and pharmacodynamic endpoints. Proc Am Soc Clin Oncol 20: 82a, 2001 (abstr 326)
36. Nagasubramanian R, Innocenti F, Ratain MJ: Pharmacogenetics in cancer treatment. Annu Rev Med 54:427-452, 2003
37. van Schaik RHN: Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther Drug Monit 26:236-240, 2004
38. Chiosis G, Huerzo H, Rosen N, et al: 17AAG: Low target binding affinity and potent cell activity-finding an explanation. Mol Cancer Ther 2:123-129, 2003
39. Egorin MJ, Lagattuta TF, Hamburger DR, et al: Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 49:7-19, 2002